Melinda E. Wilson - US grants
Affiliations: | University of Kentucky, Lexington, KY |
Area:
Neuroscience BiologyWe are testing a new system for linking grants to scientists.
The funding information displayed below comes from the NIH Research Portfolio Online Reporting Tools and the NSF Award Database.The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please sign in and mark grants as correct or incorrect matches.
High-probability grants
According to our matching algorithm, Melinda E. Wilson is the likely recipient of the following grants.Years | Recipients | Code | Title / Keywords | Matching score |
---|---|---|---|---|
1994 — 1996 | Wilson, Melinda E | F31Activity Code Description: To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.). |
Fetal Alcohol and Female Reproductive Development @ Loyola University Chicago |
0.943 |
1998 — 2000 | Wilson, Melinda E | F32Activity Code Description: To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Neuroprotective Actions of Estrogen in Cortical Explants @ University of Kentucky neuroprotectants; estrogens; cerebral cortex; neurotoxicology; apoptosis; lactate dehydrogenases; neural degeneration; estradiol; glutamates; aging; pharmacokinetics; gene expression; insulinlike growth factor; messenger RNA; organ culture; Animalia; tissue /cell culture; |
1 |
2003 | Wilson, Melinda E | R03Activity Code Description: To provide research support specifically limited in time and amount for studies in categorical program areas. Small grants provide flexibility for initiating studies which are generally for preliminary short-term projects and are non-renewable. |
@ University of Kentucky In the last 20 years, HIV infection has clearly become a major health concern. There are significant sex differences in the development and progression of AIDS. Women seroconvert at a lower viral load, fail to progress during pregnancy, often have gonadal dysfunction, and develop HIV associated dementia (HAD) twice as often as men. HAD occurs in approximately 15-30% patients with advanced HIV disease and is caused by neurodegeneration in the hippocampus, basal ganglion and cortex. Furthermore, older HIV infected individuals are more likely to have HAD as compared to younger patients. While HIV does not infect neurons directly, it can induce neurotoxicity from infected astrocytes and microglia. The virus sheds proteins (Tat and gp120) that have direct neurotoxic effects. These proteins are believed to cause neuronal cell death by initiating oxidative damage resulting in apoptosis. While clinical studies are limited, it has been shown that older women were less likely to develop HAD if they were on hormone replacement therapy as compared to those who were not. This study was small, but suggests that estrogen is an important component in the development of HAD. The proposed studies will test the hypothesis that 17beta-estradiol prevents neuronal cell death in a cortical explant model following exposure to toxic HIV proteins by suppressing apoptotic signals. The specific aims are as follows: Aim 1. To determine the characteristics of cell death following HIV protein administration in vitro. These experiments will establish cortical explant cultures as a model to study the neurotoxic actions of HIV proteins. We will perform dose response and time-course experiments to further determine the evolution of cell death following HIV protein administration. Furthermore, we will determine if cell death induced by HIV proteins occurs by apoptosis. Aim 2. To determine if 17-beta-estradiol prevents cell death following HIV protein toxicity. In these experiments, we will determine under what treatment paradigms 17beta-estradiol prevents Tat1-72 induced toxicity. In addition, we will determine if the estrogen receptor is required for this protection by the addition of an estrogen receptor antagonist. Finally, we will examine the interaction between 17beta-estradiol and apoptotic cellular signaling pathways. The studies outlined here will be critical to our understanding of the mechanisms by which estrogen protects the brain against HIV protein neurotoxicity. Understanding the mechanisms of estrogen action in a tissue specific manner is important to eventually designing estrogen therapies that target specific tissues while avoiding negative actions of estrogen in other tissues. |
1 |
2003 — 2007 | Wilson, Melinda E | R01Activity Code Description: To support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. |
Hiv Protease Inhibitors, Marcophage Function/Estrogen @ University of Kentucky [unreadable] DESCRIPTION (provided by applicant): Protease inhibitor therapy has greatly increased the lifespan of individuals infected with the human immunodeficiency virus (HIV). Unfortunately, one of the deleterious side effects of protease inhibitor therapy is dyslipidemia which is known to be closely associated with development of atherosclerosis. The development of atherosclerosis is a multifactorial process in which macrophage lipid metabolism plays a central role. In the healthy population, premenopausal women have a lower incidence of atherosclerosis as compared to men. Women on protease inhibitor therapy, however, have similar dyslipidemia as men on protease inhibitor therapy, suggesting that the cardioprotective effects of estrogen are lost. Additionally, preliminary studies in mice show that female mice have significantly fewer atherosclerotic lesions accompanied by a reduced disruption of lipid metabolism in macrophages. Therefore, this proposal will test the hypothesis that the gonadal steroid estrogen modulates the effects of HW protease inhibitors on macrophage lipoprotein metabolism and thus atherosclerotic lesion formation. Aim 1 will determine the ability of 17??estradiol to suppress HIV protease inhibitor-induced macrophage sterol accumulation. We will use the human monocyte/macrophage cell line, THP-1 to define the effects 17??estradiol on the HIV protease inhibitors ritonavir and amprenavir induced alterations of CD36 expression and CD36-dependent function by measuring lipoprotein uptake and cholesterol efflux. Aim 2 will investigate potential mechanisms by which 17??estradiol prevents macrophage dysfunction induced by HW protease inhibitors. An estrogen receptor antagonist will be administered to THP-1 cells to assess the role of estrogen receptors in the regulation of the scavenger receptor CD36 expression and function in the presence of ritonavir and/or amprenavir. We wilt also examine the expression and function of peroxisome proliferating activated receptor gamma (PPAR?) and PPAR? mRNA following estrogen treatment. Aim 3 will determine if 17??estradiol alters the development of atherosclerotic lesions induced by HW protease inhibitors in vivo. We will examine the atherosclerotlc lesion size and lipid metabolism in peritoneal macrophages from intact LDL receptor null mice as well as ovariectomized and estrogen replaced female mice. To determine if estrogen receptors are needed in vivo, LDL receptor null mice will be crossed with estrogen receptor null mice to determine if the estrogen receptors are required for estrogen to prevent atheroscterotic lesions and macrophage dysfunction following HIV protease inhibitor treatment. The data obtained from these studies will be critical to enhancing our understanding of the actions of estrogen in the cardiovascular system as well as estrogen function during HIV infection and protease inhibitor therapy. [unreadable] [unreadable] |
1 |
2009 — 2012 | Wilson, Melinda | N/AActivity Code Description: No activity code was retrieved: click on the grant title for more information |
Developmental Regulation of Estrogen Receptor-Alpha by Epigenetic Modification @ University of Kentucky Research Foundation This award is funded under the American Recovery and Reinvestment Act of 2009 (Public Law 111-5). |
0.915 |
2011 — 2015 | Wilson, Melinda | N/AActivity Code Description: No activity code was retrieved: click on the grant title for more information |
Molecular Regulation of Estrogen Receptor Gene Expression in the Adult Brain @ University of Kentucky Research Foundation This study investigates the molecular mechanisms by which critical genes are differentially regulated in the male and female brain. The hormone, estrogen, is critical for establishing structural and functional aspects of the brain in both males and females. Estrogen functions through intracellular receptors that mediate its action. Estrogen receptor gene expression is regulated differently in the male and female brain after a neural injury, however, the molecular mechanisms that regulate this expression are not known. In this study, the effects of epigenetic modification of DNA on the expression of estrogen receptors after brain injury will be examined in a rat animal model. Molecular biological and histological techniques will be used to identify these changes. It is hypothesized that estrogen receptor gene expression is differentially activated by DNA demethylation after injury. The results of this study will enhance the understanding of the inherent gender differences in the regulation of gene expression in the brain. This project combines the fields of neuroendocrinology with the rapidly growing field of epigenetics. In addition to the answering fundamental questions in the field of neuroscience, the impact of this study is enhanced by the involvement of multiple undergraduate, graduate, and postdoctoral students over the course of the study that provides a fundamental scientific background to these students. The students are involved in all aspects of this project from performing experiments to presenting the findings. All students will be encouraged to present their data at University events as well as at other regional and national meetings. Students also have the opportunity participate in community events such as those associated with Brain Awareness Week with the Society for Neuroscience. These events allow students to interact with the public to educate children and parents alike to importance of understanding how their brains function. |
0.915 |